236 related articles for article (PubMed ID: 2378356)
1. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
[TBL] [Abstract][Full Text] [Related]
2. Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1.
Labelle Y; Puymirat J; Tanguay RM
Biochim Biophys Acta; 1993 Jan; 1180(3):250-6. PubMed ID: 8422430
[TBL] [Abstract][Full Text] [Related]
3. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
[TBL] [Abstract][Full Text] [Related]
5. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
6. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
Nicole LM; Valet JP; Laberge C; Tanguay RM
Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
[TBL] [Abstract][Full Text] [Related]
7. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.
Phaneuf D; Labelle Y; Bérubé D; Arden K; Cavenee W; Gagné R; Tanguay RM
Am J Hum Genet; 1991 Mar; 48(3):525-35. PubMed ID: 1998338
[TBL] [Abstract][Full Text] [Related]
8. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
9. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
[TBL] [Abstract][Full Text] [Related]
10. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
[TBL] [Abstract][Full Text] [Related]
11. Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.
Rootwelt H; Chou J; Gahl WA; Berger R; Coşkun T; Brodtkorb E; Kvittingen EA
Hum Genet; 1994 Jun; 93(6):615-9. PubMed ID: 8005583
[TBL] [Abstract][Full Text] [Related]
12. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
Phaneuf D; Hadchouel M; Tanguay RM; Bréchot C; Ferry N
Biochem Biophys Res Commun; 1995 Mar; 208(3):957-63. PubMed ID: 7702626
[TBL] [Abstract][Full Text] [Related]
13. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.
Kvittingen EA; Rootwelt H; van Dam T; van Faassen H; Berger R
Pediatr Res; 1992 Jan; 31(1):43-6. PubMed ID: 1594329
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
15. The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency.
Rootwelt H; Kvittingen EA; Høie K; Agsteribbe E; Hartog M; van Faassen H; Berger R
Hum Genet; 1992 May; 89(2):229-33. PubMed ID: 1350265
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
St-Louis M; Tanguay RM
Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
[TBL] [Abstract][Full Text] [Related]
17. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I.
Awata H; Endo F; Tanoue A; Kitano A; Nakano Y; Matsuda I
Biochim Biophys Acta; 1994 May; 1226(2):168-72. PubMed ID: 8204664
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of fumarylacetoacetase without hereditary tyrosinemia.
Kvittingen EA; Børresen AL; Stokke O; van der Hagen CB; Lie SO
Clin Genet; 1985 Jun; 27(6):550-4. PubMed ID: 4017276
[TBL] [Abstract][Full Text] [Related]
19. Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
